Bionano Genomics Inc. (BNGO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While BNGO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.37) and Max Pain ($1.26) forces dealer call-delta covering toward $2.34.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Bionano Genomics Inc. (BNGO) slipped -0.41% to $1.20, trading at 16% of its 52-week range ($1 – $2.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time to report f
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BNGO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BNGO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Bionano Genomics Inc. (BNGO) ranks #798 by composite RQD confidence (36/100, grade D-) and #847 by equity capitalization ($16.8M). Within this direct 5-issuer industry benchmark cohort, BNGO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with BNGO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BNGO
ACTIVE
Bionano Genomics Inc. | D- | 36/100 | — | 46.3% | -35.0% | -0.41% | $16.8M | Benchmark Subject |
| ASTC Astrotech Corporation | E | 33/100 | — | 47.5% | -35.0% | -0.28% | $11.1M | /astc-vs-bngo → |
| EYPT EyePoint Inc. | D- | 38/100 | — | — | -35.0% | +0.69% | $32.8M | /eypt-vs-bngo → |
| PRPO Precipio Inc. | D- | 38/100 | — | 44.2% | -7.9% | +3.59% | $34.6M | /prpo-vs-bngo → |
| RPID Rapid Micro Biosystems Inc. (Class A) | D | 47/100 | — | — | -35.0% | -1.37% | $39.6M | /rpid-vs-bngo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bionano Genomics Inc. (BNGO) reported GAAP revenue of $28.5M (-7.4% vs. FY2024 revenue of $30.8M , and -21.1% cumulative change since FY2023) , GAAP net income of -$26.4M, operating cash flow of -$16.3M, and free cash flow of -$16.3M (+76.3% YoY). On the balance sheet, BNGO closed FY2025 with $73.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $28.5M | -$26.4M | -$16.3M | -$16.3M | $73.6M | — |
| FY2024 (FY) | 2024-12-31 | $30.8M | -$112.0M | -$68.9M | -$68.9M | $76.7M | — |
| FY2023 (FY) | 2023-12-31 | $36.1M | -$232.5M | -$125.2M | -$125.2M | — | — |
As of 2026-11-01, Bionano Genomics Inc. (NASDAQ: BNGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.20 (-0.41% 1D, market cap $16.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BNGO ranks #798 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BNGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 46.3%, and ROIC of -35.0%. By comparison, ASTC (Astrotech Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and EYPT (EyePoint Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $32.8M). Among the 5-stock peer group, BNGO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per BNGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001411690), Bionano Genomics Inc. generated $28.5M in revenue (-7.4% YoY), -$26.4M in net income, and -$16.3M in free cash flow against $73.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BNGO last traded at $1.20 (-0.41% on volume of 67,214 shares), positioning the stock -12.41% below its 50-day simple moving average ($1.37) and -3.23% below its 200-day simple moving average ($1.24). Across its 52-week range of $1.00 to $2.23, BNGO sits at the 16.3% percentile with a 14-day RSI of 34.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.05 to $1.35).
Why BNGO Stock slipped -0.41% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.